Stereotaxis (NYSEAMERICAN:STXS – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02), Zacks reports. Stereotaxis had a negative return on equity of 130.84% and a negative net margin of 74.24%. The firm had revenue of $8.93 million for the quarter, compared to analyst estimates of $9.60 million.
Here are the key takeaways from Stereotaxis’ conference call:
- GenesisX and Synchrony are beginning to contribute to capital sales. Stereotaxis reported a pipeline of a couple dozen GenesisX opportunities and about 50 Synchrony systems; the company expects upcoming GenesisX installations and new X-ray compatibility, including a collaboration with Canon, to support broader adoption.
- MAGiC catheter supply remains a major constraint. Osypka’s production did not increase in the third quarter, leaving about $1.9 million of disposable orders unfilled entering Q4. Stereotaxis expects supply relief in early 2027, pending regulatory milestones for an alternative supply source, and said the shortage continues to limit procedures and recurring revenue.
- Third-quarter revenue rose 20% year over year to $8.9 million, while recurring revenue increased 6% to $5.9 million but fell 4% sequentially. Gross margin was 45%; operating and net losses were both $6.5 million, and adjusted operating expenses increased from a year earlier, partly due to Robocath-related costs.
- Stereotaxis received $12 million upfront through a convertible-note financing and has the option to draw another $12 million after a regulatory milestone. The company said pro forma cash is $16 million, with up to $28 million available, and management sees a path to profitability next year as recurring revenue grows and capital sales become more consistent.
Stereotaxis Stock Performance
NYSEAMERICAN:STXS opened at $1.03 on Wednesday. Stereotaxis has a 52 week low of $0.80 and a 52 week high of $2.89. The firm’s 50-day simple moving average is $1.16 and its 200 day simple moving average is $1.66. The firm has a market cap of $103.21 million, a price-to-earnings ratio of -4.29 and a beta of 1.40.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on STXS shares. Citizens Jmp lowered their price target on Stereotaxis from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 27th. TD Cowen cut their price objective on Stereotaxis from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Finally, Citigroup reiterated an “outperform” rating on shares of Stereotaxis in a research note on Thursday, August 27th. Five research analysts have rated the stock with a Buy rating. According to MarketBeat.com, Stereotaxis currently has a consensus rating of “Buy” and a consensus target price of $3.38.
Get Our Latest Analysis on Stereotaxis
About Stereotaxis
Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular procedures, with a primary focus on cardiac electrophysiology. Its systems use magnetic navigation and specialized software to help physicians control guidewires and catheters during procedures such as the treatment of cardiac arrhythmias. The company’s product portfolio includes the Genesis Robotic Magnetic Navigation System, which is designed to provide precise catheter movement and navigation within the heart.
See Also
- Five stocks we like better than Stereotaxis
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.
